RT Journal Article
SR Electronic
T1 Innate immune responses in patients treated with SBRT irradiation enhances prostate cancer remissions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268830
DO 10.1101/2022.01.06.22268830
A1 Cheema, Amrita K
A1 Li, Yaoxiang
A1 Collins, Sean
A1 Suy, Simeng
A1 Ventimiglia, Mary
A1 Kowalczyk, Keith
A1 Hankins, Ryan
A1 Lynch, John
A1 Janowski, Einsley-Marie
A1 Grindrod, Scott
A1 Villagra, Alejandro
A1 Dritschilo, Anatoly
YR 2022
UL http://medrxiv.org/content/early/2022/01/07/2022.01.06.22268830.abstract
AB Stereotactic body radiation therapy (SBRT) is a curative therapeutic modality employing large fractional doses of highly conformal radiation therapy for cancer treatment. To understand the mechanisms underlying clinical responses to radiation therapy, SBRT offers a unique window for high-throughput analysis of post-radiation molecular events to inform predictive biomarker discovery and strategies for multi-disciplinary therapeutics. We performed longitudinal analysis of plasma proteins and metabolites from patients treated with prostate SBRT, comparing cohorts of patients in clinical remission to cohorts experiencing PSA-determined cancer progression. We observed onset of post-SBRT DNA Damage Response (DDR), cell cycle arrest, and immune response signaling in patients within one hour of treatment and innate immune response signaling that persisted for up to three months following treatment. Furthermore, patients in remission experienced more robust immune responses and metabolite elevations consistent with a pro-inflammatory, M1-mediated innate immune activation in the short-term following SBRT, whereas patients with disease progression had less robust immune responses and M2-mediated metabolite elevations. We interpret these data to support a critical role for innate immune activation in the clinical outcomes of patients receiving radiation therapy for prostate cancer potentially improving future multidisciplinary therapeutic strategies.One Sentence Summary Following SBRT, proteomic and metabolomic profiles reveal a robust immune activation that correlates with prostate cancer remissionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by NCI/NIH SBIR (Phases I and II) contract # HHSN261201600027C to Shuttle Pharmaceuticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of MedStar-Georgetown University Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors